What Is Tesamorelin?

Tesamorelin is one of the few compounds in the “peptide therapy” conversation that comes with a genuine FDA approval attached. That single fact changes how you should read everything else about it. Most peptides discussed online — BPC-157, the GH secretagogues, the research-only metabolic compounds — have no approval for any human use. Tesamorelin does. But that approval is narrow and specific, and understanding exactly where it begins and ends is the whole point of this page.

What tesamorelin actually is

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH). Your body makes GHRH naturally in the hypothalamus; it travels to the pituitary gland and tells it to release growth hormone. Natural GHRH is fragile and breaks down within minutes, which makes it useless as a drug. Tesamorelin is GHRH with a chemical modification on one end that protects it from rapid enzymatic breakdown, so it survives long enough to do its job after a subcutaneous injection.

The key conceptual point: tesamorelin is not growth hormone, and it is not a substitute for it. It is a signal. It works one level upstream — it prompts your own pituitary to release your own growth hormone, in your body’s own pulsatile rhythm, rather than flooding the system with injected hormone. This “secretagogue” mechanism is the same broad family that sermorelin, CJC-1295, and ipamorelin belong to, though each works through a slightly different receptor or has a different duration. If you want the orientation on those cousins, see what is sermorelin? and what is CJC-1295?, which sit alongside this page in the Reference cluster.

Note: Because tesamorelin amplifies your own growth-hormone output rather than replacing it, its effect is partly governed by your existing pituitary function. It is a nudge to a system, not an override of it.

The one thing it’s approved for

This is the section that matters most, because it is the thing almost every casual write-up gets fuzzy about.

Tesamorelin is FDA-approved under the brand name Egrifta for exactly one indication: to reduce excess visceral abdominal fat in adults living with HIV who have lipodystrophy. Lipodystrophy is a redistribution of body fat — often a buildup of deep abdominal (visceral) fat — that has historically been associated with HIV and some of its long-term treatments. Tesamorelin was first approved for this in 2010 and has remained the only medication approved in the US for that specific problem.

Everything else you might read about tesamorelin — anti-aging, general weight loss, “biohacking” body recomposition, athletic recovery — falls outside that approval. Those uses are off-label or, in the case of research-vial purchases, gray-market. The approval is a real, hard-won, narrowly-scoped thing, and it does not silently expand to cover whatever a wellness clinic wants to use it for. Keeping that boundary clear is the core literacy this page is trying to give you.

Egrifta SV and Egrifta WR

You’ll see two product names, and they confuse people. Both are tesamorelin. The older formulation was sold as Egrifta SV, reconstituted (mixed from powder) daily. In 2025 the FDA approved a newer formulation, Egrifta WR, which only needs to be reconstituted once a week and uses less than half the injection volume — a meaningful convenience improvement for people taking a daily injection. Egrifta WR is replacing Egrifta SV as the current commercial product. The active molecule is the same; the difference is formulation and handling, not a new drug.

How it differs from “research” tesamorelin

Here is where the FDA approval and the peptide marketplace part ways. Pharmacy Egrifta is a regulated biologic: manufactured to a standard, tested for identity and purity, dispensed with a prescription and a label. The tesamorelin sold by gray-market “research” peptide vendors is a different thing in practice, even if the name on the vial is identical. It is labeled “for research use only / not for human consumption,” it has not gone through the same manufacturing and release controls, and its actual content and purity cannot be assumed to match the approved product.

This isn’t a paperwork technicality. The whole value of an FDA approval is the chain of assurance behind it — that what’s in the vial is what the label says, in the amount it says. A research vial strips that chain away. So “tesamorelin is FDA-approved” and “the tesamorelin I bought online is therefore safe” are two completely different claims, and the second one does not follow from the first.

What the evidence base looks like

Because it’s an approved drug, tesamorelin has something most wellness peptides lack: real, registered human clinical trials behind its approved use. In the HIV-lipodystrophy population, studies showed measurable reductions in visceral adipose tissue versus placebo. That’s a genuine, scan-measured result in a defined patient group — not an anecdote.

What that evidence base does not do is automatically transfer to a healthy person using tesamorelin for cosmetic fat loss or longevity. The trials were run in a specific population with a specific problem. The further a use drifts from that population, the thinner the evidence supporting it becomes, regardless of how confidently it’s marketed. We keep this page to identity and orientation; for what is and isn’t actually demonstrated, see tesamorelin benefits: what’s proven, and for the visceral-versus-subcutaneous fat distinction specifically, tesamorelin for belly fat.

Its US legal and regulatory status in 2026

As of June 2026, tesamorelin (Egrifta) remains an FDA-approved prescription drug for HIV-associated lipodystrophy. It is not a scheduled controlled substance, so it is not illegal to possess in the way a controlled drug would be — but it is a prescription medicine, meaning legal access runs through a licensed prescriber and a pharmacy, not over a counter.

A few status points worth holding onto:

• Its approval covers HIV-associated lipodystrophy only. Off-label prescribing for other purposes is legally possible but is a clinical decision, not an approved indication.
• It is a prohibited substance in competitive sport under World Anti-Doping Agency (WADA) rules, classified among peptide hormones. Athletes subject to testing should treat it as a banned substance.
• Tesamorelin sits outside the wider 2026 FDA peptide reclassification story that affects compounds like BPC-157. It didn’t need to be “reclassified” because it already has a full approval — a different and stronger regulatory footing than the compounded-peptide pathway. If you’re trying to make sense of the broader landscape, are peptides legal in the US? maps how approved drugs, compounded peptides, and research-only compounds each sit differently.

Regulatory specifics can change; the above reflects the position as of this page’s last update and should be re-checked against current FDA materials before relying on it.

How people access it legally

Because tesamorelin is an approved prescription drug, the legitimate route is straightforward in shape, even if not always easy in practice: a licensed prescriber evaluates you, and if appropriate, prescribes Egrifta, which a pharmacy dispenses. For the approved indication, that typically means an HIV or infectious-disease clinician. For off-label use, any licensed prescriber can legally prescribe, but you’re then in off-label territory with the thinner evidence and insurance complications that come with it.

This is the inverse of how access works for non-approved wellness peptides, which have no pharmacy-dispensed branded product to prescribe and instead route through compounding pharmacies or gray markets. The mechanics of getting a legitimate prescription, and who can write one, are covered in how to get tesamorelin in the US. What none of these pages will give you is a self-administration protocol or sourcing instructions — dose is a clinical decision made by a prescriber for a specific patient, and buying an unverified injectable to self-dose is exactly the risk this site exists to warn about.

The bottom line

Tesamorelin is a real drug with a real, narrow FDA approval: a stabilized GHRH analog that prompts your own growth-hormone release, approved specifically to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. That approval is its defining feature — and its limit. Everything beyond that indication is off-label or gray-market, the research-vial product is not the approved drug, and the evidence that supports it in one population doesn’t automatically carry over to another. Read it as a prescription medicine with a specific job, not a free-floating wellness compound.